Development of HPLC assay method of fusidate sodium tablets
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The Korean Pharmacopoeia (KP XI), British Pharmacopoeia (BP 2013) and Japanese Pharmacopoeia contain monographs for the quality control of raw fusidate sodium and its formulations using high performance liquid chromatography (HPLC). However, the assay method for the determination of fusidate sodium in commercial tablets is titration which is less specific than HPLC. In this study, we present an alternative HPLC method for quantitation of fusidate sodium in tablets. Method validation was performed to determine linearity, precision, accuracy, system suitability, and robustness. The linearity of calibration curves in the desired concentration range was high (r2 = 0.9999), while the RSDs for intra- and inter-day precision were 0.25-0.37% and 0.11-0.60 %, respectively. Accuracies ranged from 99.46-100.85 %. Since the system suitability, intermediate-precision and robustness of the assay were satisfactory, this method will be a valuable addition to the Korean Pharmacopoeia (KP XI).
Abstract
The Korean Pharmacopoeia (KP XI), British Pharmacopoeia (BP 2013) and Japanese Pharmacopoeia contain monographs for the quality control of raw fusidate sodium and its formulations using high performance liquid chromatography (HPLC). However, the assay method for the determination of fusidate sodium in commercial tablets is titration which is less specific than HPLC. In this study, we present an alternative HPLC method for quantitation of fusidate sodium in tablets. Method validation was performed to determine linearity, precision, accuracy, system suitability, and robustness. The linearity of calibration curves in the desired concentration range was high (r2 = 0.9999), while the RSDs for intra- and inter-day precision were 0.25-0.37% and 0.11-0.60 %, respectively. Accuracies ranged from 99.46-100.85 %. Since the system suitability, intermediate-precision and robustness of the assay were satisfactory, this method will be a valuable addition to the Korean Pharmacopoeia (KP XI).
참고문헌 (15)
- Merck Research Laboratories, "The Merck Index", ~ (2006)
- A. H. Hikal, , J. Pharm. Sci, 71(11), pp.1297~1298 (1982)
- The Ministry of Health, Labour and Welfare, "The Japanese Pharmacopoeia" (2016)
- Ministry of Food and Drug Safety, "The Korean Pharmacopoeia" (2014)
- Medicines & Healthcare Products Regulatory Agency, "British Pharmacopoeia" (2013)
- The United States Pharmacopeial Convention, "The United States Pharmacopeia, USP 39 NF 34", ~ (2016)
- J. Byrne, , J. Pharm. Biomed. Anal, 96, pp.111~117 (2014)
- S. Shaikh, , J. Chromato. Sci, 47, pp.178~183 (2009)
- M. Nawaz, , Acta Chromatogr, 26, pp.57~66 (2014)
- J. Byrne, , J. Chromato. Sci, 53, pp.1498~1503 (2015)
- H. Sorensen, , J. Chromatography, 430, pp.400~408 (1988)
- R. Leclercq, , J. Antimicrob. Chemother, 45(1), pp.27~29 (2000)
- "ICH Guideline. Q2(R1): validation of Analytical Procedures: Text and Methodology Q2(R1) in ICH Harmonised Tripartite Guideline", ~ (2005)
- "Ministry of Food and Drug Safety No. 2009-173", ~ (2009)
- "Ministry of Food and Drug Safety, No. C0-2012-2-005", ~ (2012)